Investigating the role of Elanzapine in reducing nausea and vomiting caused by chemotherapy in patients undergoing chemotherapy
Phase 1
- Conditions
- ausea and vomiting caused by chemotherapy.Nausea and vomiting
- Registration Number
- IRCT20210415050976N14
- Lead Sponsor
- Jahrom University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
Patients over 18 years of age with pathologically or cytologically confirmed malignancy
Patients undergoing emtogenic chemotherapy including carboplatin, irinotecan, cyclophosphamide
Serum creatinine =2.0 mg/dl.
Written informed consent
Exclusion Criteria
being pregnant
Suffering from cognitive diseases and neurological diseases
Treatment with another psychiatric medication such as risperidone, quetiapine, clozapine, phenothiazine, or butyrophenone within 30 days before or during protocol treatment
Simultaneous abdominal radiotherapy
Simultaneous use of quinolone antibiotic treatment
Chronic alcoholism
Hypersensitivity to olanzapine
Known heart disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Complete response to treatment as defined by the absence of nausea and vomiting or the need to receive adjuvant medication. Timepoint: Starting on the first day of treatment with olanzapine (day-2) and daily until day 5. Method of measurement: Using the Visual Analogue Scale.
- Secondary Outcome Measures
Name Time Method Duration of nausea. Timepoint: Starting on the first day of treatment with olanzapine (day-2) and daily until day 5. Method of measurement: According to the length of time the person has been nauseous.;Number of vomiting. Timepoint: Starting on the first day of treatment with olanzapine (day-2) and daily until day 5. Method of measurement: According to the number of times the person has vomited.